Download Sample Global Virus Like Particles Market and Clinical Trial Insight 2023

“Global Virus Like Particles Market and Clinical Trial Insight 2023” report highlights:

Advances in Virus like Particles as a Vaccination
Production Process of Virus like Particle based Vaccines
Market Analysis of Virus like Particles Vaccines
Global Virus Like Particle Vaccines Clinical Pipeline Insight: 60 Vaccines
Marketed Virus Like Particle Vaccines Clinical Insight: 5 Vaccines
Future Perspective of Virus like Particles Vaccines

For Report Sample Contact: neeraj@kuickresearch.com

Report Weblink:https://www.kuickresearch.com/report-global-virus-like-particles-market-and-clinical-trial-insight-2023.php

Table of Contents

1. Virus like Particles andndash; New Generation of Vaccines
1.1 Introduction
1.2 Requirements for Virus like Particles Assembly

2. Virus Candidates for Development of Virus like Particle Vaccines
2.1 Animal Virus-like Particles as Vaccine Immunogens
2.2 Plant Virus based Virus like Particles

3. Current Advances in Virus like Particles as a Vaccination Approach against Infectious Diseases
3.1 HIV-1 Virus like Particles
3.2 Hepatitis C Virus
3.3 Malaria
3.4 Newcastle Disease
3.5 Filoviruses
3.6 Norovirus

4. Production Process of Virus like Particle based Vaccines
4.1 Expression Systems
4.2 Downstream Processing of Virus like Particle Based Vaccines

5. Market Analysis of Virus like Particles Vaccines
5.1 Introduction
5.2 Market of Virus like Particle Vaccines

6. Global Virus Like Particle Vaccines Clinical Pipeline Overview

7. Global Virus like Particle Vaccines Market Dynamics
7.1 Favorable Parameters
7.2 Commercialization Challenges

8. Future Perspective of Virus like Particles Vaccines

9. Global Virus Like Particle Vaccines Clinical Pipeline by Company, Indication and Phase
9.1 Research
9.2 Preclinical
9.3 Phase-I
9.4 Phase-I/II
9.5 Phase-II
9.6 Phase-II/III
9.7 Phase-III

10. Marketed Virus Like Particle Vaccines Clinical Insight
10.1 Human papillomavirus vaccine recombinant quadrivalent (Gardasil and Silgard)
10.2 Human papillomavirus vaccine recombinant bivalent (Cervarix)
10.3 Human Papillomavirus Vaccine Recombinant Nonavalent (GARDASIL9)
10.4 Influenza Virus Vaccine Trivalent (CadiFlu-S)
10.5 Influenza A Virus H1N1 Vaccine (CadiFlu)

11. Competitive Landscape
11.1 Agilvax
11.2 Allergy Therapeutics
11.3 ANGANY Genetics
11.4 CPL Biologicals
11.5 Cytos Biotechnology
11.6 GeoVax Labs
11.7 GlaxoSmithKline
11.8 Medicago
11.9 MedImmune
11.10 Merck
11.11 Novavax
11.12 Serum Institute of India
11.13 Takeda
11.14 TechnoVax
11.15 Xiamen Innovax Biotech

Figure 1-1: Non-Enveloped Virus like Particle Production through Pathogen Component and Fusion to a Vaccine Target Antigen
Figure 1-2: Diagram of Enveloped Virus like Particle Production
Figure 1-3: Requirements for the Assembly of Virus like Particles
Figure 2-1: Types of Plant Virus for Virus like Particles Development
Figure 3-1: Modification of HIV-1 Envelope Trimers for Virus like Particle Vaccine
Figure 3-2: Virus like Particle Vaccine Strategy against Hepatitis C virus
Figure 3-3: New Castle Virus for Virus like Particle Vaccine Development
Figure 3-4: Production of Ebola Virus like Particles from Plasmids
Figure 4-1: Downstream Process Strategy for Virus like Particle Purification
Figure 5-1: Global - Market Growth Potential of Vaccine Industry (US$, Billion), 2017-2023
Figure 6-1: Global andndash; Virus Like Particle Vaccines Pipeline by Phase (%), 2017 till 2023
Figure 6 2: Global andndash;Virus Like Particle Vaccines Pipeline by Phase (Number), 2017 till 2023
Figure 6-3: Global andndash; Virus Like Particle Vaccines Pipeline by Phase (%),2017 till 2023
Figure 6-4: Global andndash; Virus Like Particle Vaccines Pipeline by Phase (Number), 2017 till 2023
Figure 7-1: Favorable Market Parameters for Vaccine Development
Figure 7-2: Challenges to the Market Growth of Vaccines
Figure 8-1: Future Scientific Innovations and Challenges for Vaccine Development

Table 3-1: Development Status of Virus like Particle Vaccine Candidates
Table 4-1: Properties of Various Expression Systems for Production of Virus like Particle

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
New Delhi-110001
India
+91-11-47067990

This release was published on openPR.